IL33 and Alzheimer disease: All studies confirmed the pharmacodynamic effect, including target saturation and reduction in inflammation biomarkers; however, the lack of translation into significant clinical improvement suggests that the role of IL-33 in the pathogenesis of AD is context-dependent and limited to specific disease endotypes.